Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 16

1.

A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.

Sotiriou E, Goussi C, Lallas A, Chovarda E, Apalla Z, Lazaridou E, Ioannides D.

J Drugs Dermatol. 2012 May;11(5 Suppl):s15-20.

PMID:
22644772
2.

Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.

van der Zee HH, Laman JD, de Ruiter L, Dik WA, Prens EP.

Br J Dermatol. 2012 Feb;166(2):298-305. doi: 10.1111/j.1365-2133.2011.10698.x.

PMID:
22013960
3.

A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.

Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB.

Br J Dermatol. 2011 Aug;165(2):391-8. doi: 10.1111/j.1365-2133.2011.10339.x. Epub 2011 Jun 30.

PMID:
21457202
4.

Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.

van Rappard DC, Leenarts MF, Meijerink-van 't Oost L, Mekkes JR.

J Dermatolog Treat. 2012 Aug;23(4):284-9. doi: 10.3109/09546634.2011.571657. Epub 2011 Jul 14.

PMID:
21756155
5.

Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.

Arenbergerova M, Gkalpakiotis S, Arenberger P.

Int J Dermatol. 2010 Dec;49(12):1445-9. doi: 10.1111/j.1365-4632.2010.04638.x.

PMID:
21091684
6.

Long-term successful adalimumab therapy in severe hidradenitis suppurativa.

Blanco R, Martínez-Taboada VM, Villa I, González-Vela MC, Fernández-Llaca H, Agudo M, González-López MA.

Arch Dermatol. 2009 May;145(5):580-4. doi: 10.1001/archdermatol.2009.49.

PMID:
19451504
7.

Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.

Reddick CL, Singh MN, Chalmers RJ.

Dermatol Online J. 2010 Aug 15;16(8):15.

PMID:
20804692
8.

Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.

Harde V, Mrowietz U.

J Dtsch Dermatol Ges. 2009 Feb;7(2):139-41. doi: 10.1111/j.1610-0387.2008.06918.x. English, German.

PMID:
19371236
9.

Hidradenitis suppurativa managed with adalimumab.

Yamauchi PS, Mau N.

J Drugs Dermatol. 2009 Feb;8(2):181-3.

PMID:
19213236
10.

A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.

Amano M, Grant A, Kerdel FA.

Int J Dermatol. 2010 Aug;49(8):950-5. doi: 10.1111/j.1365-4632.2010.04545.x.

PMID:
21128923
11.

Interstitial keratitis secondary to severe hidradenitis suppurativa responding to adalimumab.

Blanco R, González-Vela MC, González-López MA, Fernández-Llaca H, Cañal J, González-Gay MA.

Cornea. 2012 Feb;31(2):206; author reply 206. doi: 10.1097/ICO.0b013e31820ce137. No abstract available.

PMID:
22146546
12.

Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab.

Gorovoy I, Berghoff A, Ferris L.

Case Rep Dermatol. 2009 Oct 27;1(1):71-77.

13.

Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.

Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB.

Ann Intern Med. 2012 Dec 18;157(12):846-55. doi: 10.7326/0003-4819-157-12-201212180-00004.

PMID:
23247938
14.

Efficacy of adalimumab in recalcitrant hidradenitis suppurativa.

Sotiriou E, Apalla Z, Vakirlis E, Ioannides D.

Eur J Dermatol. 2009 Mar-Apr;19(2):180-1. doi: 10.1684/ejd.2008.0599. Epub 2009 Jan 20. No abstract available.

PMID:
19153066
15.

The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.

Moul DK, Korman NJ.

Arch Dermatol. 2006 Sep;142(9):1110-2. No abstract available.

PMID:
16982997
16.

Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.

[No authors listed]

Ann Intern Med. 2012 Dec 18;157(12):I-50. doi: 10.7326/0003-4819-157-12-201212180-00001. No abstract available.

PMID:
23247950

Supplemental Content

Support Center